Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
2. Pf 03084014
3. Pf 3084014
4. Pf-03084014
5. Pf-3084014
6. Pf03084014
7. Pf3084014
1. Pf-03084014
2. 1290543-63-3
3. Pf-3084014
4. 865773-15-5
5. Pf 3084014
6. Nirogacestat [usan]
7. Pf 03084014
8. Pf3084014
9. Qz62892ofj
10. (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
11. (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide
12. Pf-03084014 (pf-3084014)
13. (s)-2-((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
14. Unii-qz62892ofj
15. Nirogacestat (usan/inn)
16. Nirogacestat [inn]
17. Z-3181
18. Nirogacestat [who-dd]
19. Gtpl7746
20. Chembl1770916
21. Schembl13184754
22. Dtxsid60235679
23. Ex-a855
24. Pf-3084014 (y-secratase)
25. Hms3886p21
26. Bdbm50458159
27. Mfcd19980705
28. Nsc754348
29. S8018
30. Zinc38217837
31. Akos030526383
32. Ccg-269609
33. Cs-1689
34. Db12005
35. Nsc-754348
36. Ncgc00378713-01
37. 2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
38. Ac-36191
39. As-56178
40. Hy-15185
41. Pf-03084014-pf-3084014
42. A11993
43. D10960
44. F17429
45. A910640
46. Nirogacestat (pf-03084014, Pf-3084014)
47. Q27088329
48. Pf-03084014;pf-3084014;865773-15-5;
49. (2s)-2-(((2s)-6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino)-n-(1-(2-((2,2-dimethylpropyl)amino)-1,1-dimethylethyl)-1h-imidazol-4-yl)pentanamide
50. (2s)-2-{[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino}-n-(1-{1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl}-1h-imidazol-4-yl)pentanamide
51. Pentanamide, 2-(((2s)-6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino)-n-(1-(2-((2,2-dimethylpropyl)amino)-1,1-dimethylethyl)-1h-imidazol-4-yl)-, (2s)-
52. Pentanamide, 2-((6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino)-n-(1-(2-((2,2-dimethylpropyl)amino)-1,1-dimethylethyl)-1h-imidazol-4-yl)-, (2s)-
53. Pentanamide, 2-[(6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-n-[1-[2-[(2,2-dimethylpropyl)amino]-1,1-dimethylethyl]-1h-imidazol-4-yl]-, (2s)
| Molecular Weight | 489.6 g/mol |
|---|---|
| Molecular Formula | C27H41F2N5O |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Exact Mass | 489.32791727 g/mol |
| Monoisotopic Mass | 489.32791727 g/mol |
| Topological Polar Surface Area | 71 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 685 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Gamma Secretase Inhibitors and Modulators
Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types. (See all compounds classified as Gamma Secretase Inhibitors and Modulators.)
API SUPPLIERS
Date of Issue : 2022-07-26
Valid Till : 2025-07-14
Written Confirmation Number : WC-0130
Address of the Firm :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
Nirogacestat Hydrobromide (IH)
Date of Issue : 2022-07-26
Valid Till : 2025-07-14
Written Confirmation Number : WC-0130
Address of the Firm : Plot No. 79B, 80A, 80B, 81A, &82, Kolhar Industrial Area, Bidar, Karnataka -5854...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Ogsiveo (nirogacestat) is a USFDA approved oral, selective, small molecule gamma secretase inhibitor. It is being evaluated for the treatment of adults with desmoid tumors.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: Ogsiveo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SpringWorks Announces EMA Validation for Nirogacestat in Adults with Desmoid Tumors
Details : Ogsiveo (nirogacestat) is a USFDA approved oral, selective, small molecule gamma secretase inhibitor. It is being evaluated for the treatment of adults with desmoid tumors.
Brand Name : Ogsiveo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 29, 2024
Details:
The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development activities.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: Ogsiveo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $316.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $316.2 million
Deal Type : Public Offering
Details : The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development ...
Brand Name : Ogsiveo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 08, 2023
Details:
The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development activities.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: Ogsiveo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $275.0 million
Deal Type : Public Offering
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Details : The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development ...
Brand Name : Ogsiveo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2023
Details:
The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development activities.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: Ogsiveo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $287.5 million
Deal Type : Public Offering
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
Details : The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development ...
Brand Name : Ogsiveo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2023
Details:
Ogsiveo (nirogacestat) is an investigational gamma secretase inhibitor which is approved by USFDA as the first and only treatment for adults with desmoid tumors.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: Ogsiveo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ogsiveo (nirogacestat) is an investigational gamma secretase inhibitor which is approved by USFDA as the first and only treatment for adults with desmoid tumors.
Brand Name : Ogsiveo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 27, 2023
Details:
Ogsiveo (nirogacestat) is an investigational gamma secretase inhibitor which is approved by USFDA as the first and only treatment for adults with desmoid tumors.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: Ogsiveo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors
Details : Ogsiveo (nirogacestat) is an investigational gamma secretase inhibitor which is approved by USFDA as the first and only treatment for adults with desmoid tumors.
Brand Name : Ogsiveo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 27, 2023
Details:
PF-03084014 (nirogacestat) is an investigational gamma secretase inhibitor being develop in patients with treatment of adults with desmoid tumors. PDUFA date has been extended by the standard extension period of three months.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: PF-03084014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
Details : PF-03084014 (nirogacestat) is an investigational gamma secretase inhibitor being develop in patients with treatment of adults with desmoid tumors. PDUFA date has been extended by the standard extension period of three months.
Brand Name : PF-03084014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2023
Details:
PF-03084014 (nirogacestat) is an investigational gamma secretase inhibitor being develop in patients with recurrent ovarian granulosa cell tumors (OvGCT).
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: PF-03084014
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PF-03084014 (nirogacestat) is an investigational gamma secretase inhibitor being develop in patients with recurrent ovarian granulosa cell tumors (OvGCT).
Brand Name : PF-03084014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2023
Details:
PF-03084014 (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors and in Phase 2 clinical development for ovarian granulosa cell tumors.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: PF-03084014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PF-03084014 (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors and in Phase 2 clinical development for ovarian granulosa cell tumors.
Brand Name : PF-03084014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2023
Details:
PF-03084014 (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor in phase 3 clinical development for desmoid tumors and in phase 2 clinical development for ovarian granulosa cell tumors.
Lead Product(s): Nirogacestat Hydrobromide
Therapeutic Area: Oncology Brand Name: PF-03084014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Lead Product(s) : Nirogacestat Hydrobromide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PF-03084014 (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor in phase 3 clinical development for desmoid tumors and in phase 2 clinical development for ovarian granulosa cell tumors.
Brand Name : PF-03084014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
